4.6 Article

Neurophysiological and clinical responses to rituximab in patients with anti-MAG polyneuropathy

Journal

CLINICAL NEUROPHYSIOLOGY
Volume 122, Issue 12, Pages 2518-2522

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.clinph.2011.05.015

Keywords

Anti-MAG polyneuropathy; CD20 B-lymphocytes; Disability scale; INCAT sensory sum score; Electrodiagnostic studies; Rituximab

Ask authors/readers for more resources

Objectives: Rituximab treatment has shown clinical improvement in anti-myelin associated glycoprotein (MAG) polyneuropathy. We analyzed scores of clinical scales and the most sensitive electrophysiological parameters before and after immunomodulating treatment with rituximab in a group of patients affected by anti-MAG demyelinating polyneuropathy. Methods: Clinical scores, the percentage of CD20 B-lymphocytes, anti-MAG antibody titers and electrophysiological data in 7 patients with anti-MAG polyneuropathy were analyzed. The patients were examined before a cycle with rituximab, 6, 12 and 24 months after the end of the treatment. Two patients were treated with rituximab additional cycles and re-evaluated 48 months after the first treatment. Results: There were no evident correlation between anti-MAG serum antibody titers or clinical scales and electrodiagnostic data. Significant decrease in the proportion of CD20 B-lymphocytes was observed. Significant anti-MAG antibodies titers reduction was detected after re-treatment. At follow-up, pinprik sensation and two point discrimination presented a significant improvement compared with the score before treatment. Conclusions: In our patients, rituximab did not improve any electrophysiological data. No correlation with anti-MAG serum antibodies course was found. With rituximab only pin sensibility improved. Significance: Rituximab re-treatment significantly reduces anti-MAG serum antibodies titers but improves only small fibers sensibility. (C) 2011 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available